Suppr超能文献

在保留到中度肾功能损害的狼疮性肾炎中,肾小管间质损伤可预测终末期肾病:一项回顾性队列研究。

Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study.

机构信息

Division of Rheumatology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.

Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

出版信息

Semin Arthritis Rheum. 2018 Feb;47(4):545-551. doi: 10.1016/j.semarthrit.2017.07.007. Epub 2017 Jul 14.

Abstract

OBJECTIVES

The presence of tubulointerstitial damage (TID) on renal biopsy is considered to be a late sequela of lupus nephritis (LN). The objective of this study was to determine if TID predicts progression to end stage renal disease (ESRD) in LN patients without advanced kidney disease.

METHODS

All SLE patients with an index biopsy consistent with LN between January 2005 and July 2015, and eGFR ≥ 30mL/min/1.73m were included. Moderate-to-severe TID was defined as the presence of moderate-to-severe tubular atrophy and/or interstitial fibrosis. Time to ESRD was defined as time from the index biopsy date to incident ESRD date; non-ESRD patients were censored at the time of death or the last visit before December 2015. Time-dependent analyses were conducted to evaluate whether moderate-to-severe TID was predictive of ESRD progression.

RESULTS

Of the 131 LN patients with eGFR ≥ 30mL/min/1.73m, 17 (13%) patients progressed to ESRD. Moderate-to-severe TID was present in 13% of biopsies with eGFR ≥ 60mL/min/1.73m and in 33% of biopsies with eGFR between 30 and 60mL/min/1.73m. Moderate-to-severe TID was associated with a higher risk of ESRD progression: adjusted hazard ratio (HR) = 4.1, 95% CI: 1.4-12.1, p = 0.01 for eGFR ≥ 30mL/min/1.73m; HR = 6.2, 95% CI: 1.7-23.2, p = 0.008 for eGFR ≥ 60mL/min/1.73m. There was no association between tubulointerstitial inflammation (TII) and ESRD progression.

CONCLUSIONS

Moderate-to-severe TID, but not TII, was a strong predictor of ESRD progression independent of eGFR or glomerular findings, therefore, providing an important window for potential early interventions.

摘要

目的

肾活检中存在小管间质性损伤(TID)被认为是狼疮性肾炎(LN)的晚期后遗症。本研究的目的是确定在没有晚期肾脏疾病的 LN 患者中,TID 是否预测进展为终末期肾病(ESRD)。

方法

所有 2005 年 1 月至 2015 年 7 月间符合 LN 且 eGFR≥30mL/min/1.73m 的SLE 患者均纳入研究。中重度 TID 定义为存在中重度肾小管萎缩和/或间质纤维化。ESRD 发生时间定义为从指数活检日期到 ESRD 发生日期的时间;非 ESRD 患者在 2015 年 12 月前最后一次就诊或死亡时被删失。进行时间依赖性分析以评估中重度 TID 是否与 ESRD 进展相关。

结果

在 131 例 eGFR≥30mL/min/1.73m 的 LN 患者中,17 例(13%)患者进展为 ESRD。eGFR≥60mL/min/1.73m 的活检中有 13%存在中重度 TID,而 eGFR 在 30 至 60mL/min/1.73m 的活检中有 33%存在中重度 TID。中重度 TID 与 ESRD 进展风险较高相关:调整后的风险比(HR)=4.1,95%CI:1.4-12.1,p=0.01,用于 eGFR≥30mL/min/1.73m;HR=6.2,95%CI:1.7-23.2,p=0.008,用于 eGFR≥60mL/min/1.73m。TII 与 ESRD 进展之间无关联。

结论

中重度 TID 而不是 TII 是独立于 eGFR 或肾小球发现的 ESRD 进展的强烈预测因子,因此为潜在的早期干预提供了重要窗口。

相似文献

2
Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis.
Clin J Am Soc Nephrol. 2017 May 8;12(5):734-743. doi: 10.2215/CJN.10601016. Epub 2017 May 4.
7
[Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage].
Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Dec 18;54(6):1094-1098. doi: 10.19723/j.issn.1671-167X.2022.06.006.
9
Total cortical interstitial inflammation predicts chronic kidney disease progression in patients with lupus nephritis.
Nephrol Dial Transplant. 2023 May 31;38(6):1469-1476. doi: 10.1093/ndt/gfac286.
10
Echocardiographic Measures and Estimated GFR Decline Among African Americans: The Jackson Heart Study.
Am J Kidney Dis. 2017 Aug;70(2):199-206. doi: 10.1053/j.ajkd.2016.11.022. Epub 2017 Jan 28.

引用本文的文献

3
Correlation between serum complement component 4 levels and tubular atrophy in patients with lupus nephritis.
Ren Fail. 2025 Dec;47(1):2477833. doi: 10.1080/0886022X.2025.2477833. Epub 2025 Mar 17.
6
II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.
Adv Rheumatol. 2024 Jun 18;64(1):48. doi: 10.1186/s42358-024-00386-8.
8
Kidney Biopsy in Management of Lupus Nephritis: A Case-Based Narrative Review.
Kidney Med. 2023 Dec 6;6(2):100772. doi: 10.1016/j.xkme.2023.100772. eCollection 2024 Feb.
10
Urine Proteomics Link Complement Activation with Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients.
Semin Arthritis Rheum. 2023 Dec;63:152263. doi: 10.1016/j.semarthrit.2023.152263. Epub 2023 Sep 27.

本文引用的文献

1
Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.
Transl Res. 2017 Apr;182:1-13. doi: 10.1016/j.trsl.2016.10.010. Epub 2016 Nov 1.
2
Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology.
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2054-2060. doi: 10.2215/CJN.13651215. Epub 2016 Sep 14.
3
Overview of pathophysiology and treatment of human lupus nephritis.
Curr Opin Rheumatol. 2016 Sep;28(5):460-7. doi: 10.1097/BOR.0000000000000319.
4
Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review.
Clin Rev Allergy Immunol. 2017 Apr;52(2):149-163. doi: 10.1007/s12016-016-8533-z.
6
What is damaging the kidney in lupus nephritis?
Nat Rev Rheumatol. 2016 Mar;12(3):143-53. doi: 10.1038/nrrheum.2015.159. Epub 2015 Nov 19.
7
The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future.
Semin Nephrol. 2015 Sep;35(5):465-77. doi: 10.1016/j.semnephrol.2015.08.008.
8
The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.
Semin Nephrol. 2015 Sep;35(5):455-64. doi: 10.1016/j.semnephrol.2015.08.007.
9
Renal involvement in primary Sjögren syndrome.
Nat Rev Nephrol. 2016 Feb;12(2):82-93. doi: 10.1038/nrneph.2015.174. Epub 2015 Nov 16.
10
The frequency and outcome of lupus nephritis: results from an international inception cohort study.
Rheumatology (Oxford). 2016 Feb;55(2):252-62. doi: 10.1093/rheumatology/kev311. Epub 2015 Sep 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验